These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37156035)

  • 1. Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis.
    Boldrini VO; Mader S; Kümpfel T; Meinl E
    Mult Scler Relat Disord; 2023 Jul; 75():104733. PubMed ID: 37156035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis.
    Jakimovski D; Weinstock-Guttman B; Zivadinov R
    Expert Rev Neurother; 2023; 23(12):1053-1061. PubMed ID: 37842819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
    Frisch ES; Pretzsch R; Weber MS
    Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review.
    Azhar A; Taimuri MA; Shamat SF; Ikram A; Ali S; Ali T; Khabir Y
    Ann Med Surg (Lond); 2023 Oct; 85(10):4909-4912. PubMed ID: 37811115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ublituximab: First Approval.
    Lee A
    Drugs; 2023 Apr; 83(5):455-459. PubMed ID: 36920653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.
    Cotchett KR; Dittel BN; Obeidat AZ
    Mult Scler Relat Disord; 2021 Apr; 49():102787. PubMed ID: 33516134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
    de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
    Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
    Kaegi C; Wuest B; Crowley C; Boyman O
    Front Immunol; 2021; 12():788830. PubMed ID: 35185862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
    Delgado SR; Faissner S; Linker RA; Rammohan K
    J Neurol; 2024 Apr; 271(4):1515-1535. PubMed ID: 37906325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?
    Doggrell SA
    Expert Opin Biol Ther; 2022 Nov; 22(11):1339-1343. PubMed ID: 36317532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ofatumumab for relapsing forms of multiple sclerosis.
    Gajofatto A; Orlandi R
    Drugs Today (Barc); 2022 Jan; 58(1):9-21. PubMed ID: 35107090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
    Ancau M; Berthele A; Hemmer B
    Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
    Fox E; Lovett-Racke AE; Gormley M; Liu Y; Petracca M; Cocozza S; Shubin R; Wray S; Weiss MS; Bosco JA; Power SA; Mok K; Inglese M
    Mult Scler; 2021 Mar; 27(3):420-429. PubMed ID: 32351164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapies for multiple sclerosis targeting B cells.
    Milo R
    Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
    Sellebjerg F; Blinkenberg M; Sorensen PS
    CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
    Steinman L; Fox E; Hartung HP; Alvarez E; Qian P; Wray S; Robertson D; Huang D; Selmaj K; Wynn D; Cutter G; Mok K; Hsu Y; Xu Y; Weiss MS; Bosco JA; Power SA; Lee L; Miskin HP; Cree BAC;
    N Engl J Med; 2022 Aug; 387(8):704-714. PubMed ID: 36001711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy.
    Martin SJ; Guenette M; Oh J
    Drug Des Devel Ther; 2024; 18():3025-3042. PubMed ID: 39050801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
    Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA
    CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
    Pukoli D; Vécsei L
    Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.